These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 39290710)

  • 1. Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database.
    Liu W; Lin S; Zhu X; Yin L; Liu Q; Lei S; Feng B
    Front Immunol; 2024; 15():1433075. PubMed ID: 39290710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
    Storgard R; Dusza S; Shouval R; Scordo M; Markova A
    Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
    Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
    Front Immunol; 2022; 13():991092. PubMed ID: 36119032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
    Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.
    Wesson W; Dima D; Suleman N; Saif MSI; Tabak C; Logan E; Davis JA; McGann M; Furqan F; Mohan M; Rashid A; Abdallah AO; Ullah F; Shune L; Mushtaq MU; Raza S; McGuirk J; Hamadani M; Anwer F; Hashmi H; Ahmed N
    Transplant Cell Ther; 2024 Sep; 30(9):876-884. PubMed ID: 38871056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database.
    Fusaroli M; Isgrò V; Cutroneo PM; Ferrajolo C; Cirillo V; Del Bufalo F; Raschi E; Poluzzi E; Trifirò G
    Drug Saf; 2022 Aug; 45(8):891-908. PubMed ID: 35829913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.
    Hansen DK; Dhakal B; Hamadani M; Dingli D; Jain T; Huff CA; Janakiram M; Liu YH; De Braganca KC; Lodowski N; Sander J; Okorozo P; McFarland L; Perciavalle M; Huo S; Qureshi ZP; Patel KK
    Front Immunol; 2024; 15():1405452. PubMed ID: 38915401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma.
    Jagannath S; Jackson CC; Schecter JM; Lendvai N; Sun H; Akram M; Patel N; Martin TG
    Expert Opin Biol Ther; 2024 May; 24(5):339-350. PubMed ID: 38738379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017-2023).
    Shi J; Liu X; Jiang Y; Gao M; Yu J; Zhang Y; Wu L
    Front Pharmacol; 2024; 15():1434231. PubMed ID: 39234101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison.
    Bar N; Diels J; van Sanden S; Mendes J; Hernando T; Burnett H; Cost P; Schecter JM; Lendvai N; Patel N; Ishida T; Er J; Harrison SJ; Lopez-Muñoz N
    Curr Med Res Opin; 2024 Sep; 40(9):1597-1603. PubMed ID: 39129504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.
    Guo Z; Ding Y; Wang M; Zhai Q; Liu J; Du Q
    Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
    Ren X; Zhang G; Li G; Wang Y
    BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
    Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
    Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciltacabtagene autoleucel for the treatment of multiple myeloma.
    Holstein SA
    Drugs Today (Barc); 2023 Jan; 59(1):1-16. PubMed ID: 36811414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
    Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ
    J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
    Jagannath S; Joseph N; Crivera C; Kharat A; Jackson CC; Valluri S; Cost P; Phelps H; Slowik R; Klein T; Smolen L; Yu X; Cohen AD
    Oncol Ther; 2023 Jun; 11(2):263-275. PubMed ID: 37014590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.
    Hansen DK; Lu X; Puglianini OC; Sorensen S; Usmani SZ; Zhang E; Huo S; Zhang Y; Qureshi ZP; Jagannath S
    Front Immunol; 2024; 15():1408892. PubMed ID: 39234256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.